Flt3 Kinase Modulation for Acute Myeloid Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by abnormally activated Flt3 kinase, such as acute myeloid leukemia, are inadequate due to the limited effectiveness of existing therapies in targeting mutant Flt3 kinases.
Innovation Solution
Development of compounds, specifically those of Formula I and its sub-formulas, which modulate Flt3 kinase activity by administering therapeutically effective amounts to subjects at risk or suffering from Flt3-mediated diseases, thereby inhibiting the kinase's abnormal activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat Flt3 kinase-mediated diseases, then treatment can be administered, but the effectiveness is limited and inadequate
Solution Approach 1:
The patent develops novel compounds with modified chemical structures (Formula I and sub-formulas) that specifically target mutant Flt3 kinases. By changing the molecular parameters and structural characteristics of the therapeutic agents, the invention achieves improved binding affinity and selectivity for mutant forms of Flt3, thereby resolving the limitation of existing therapies that cannot effectively target these mutants
Solution Approach 2:
The patent identifies and targets specific mutant variants of Flt3 kinase through separately claimed compound series (Formula I, II, III, IV, V and their sub-formulas). Each formula represents a segmented approach to addressing different mutant types, allowing tailored therapeutic strategies for specific Flt3 mutations while maintaining overall treatment effectiveness
2Reliability
If compounds of Formula I are administered to inhibit Flt3 kinase activity, then abnormal kinase activity is effectively inhibited, but potential off-target effects and toxicity may occur
Solution Approach 1:
The patent designs compounds with specific structural features (substituents at defined positions in Formula I, II, III, IV, V) that provide localized interaction with specific residues in the Flt3 kinase binding pocket. This local quality enhancement through targeted molecular design improves selectivity for Flt3 over other kinases, reducing off-target effects while maintaining potent inhibition of abnormal Flt3 activity
Solution Approach 2:
The patent employs carefully designed molecular intermediaries (the compounds of Formula I and sub-formulas) that mediate the interaction between the therapeutic agent and the Flt3 kinase. These intermediary compounds are structurally optimized to provide selective binding to Flt3 mutant forms while minimizing non-specific interactions with other biological targets, thus reducing toxicity
Data Source
AI summary
Compounds, compositions and methods useful for treatment of Flt3-mediated diseases or conditions are provided herewith. Also provided herewith are methods for modulating the receptor protein tyrosine like kinase 3(Flt3).